Remove Compliance Remove Drug Delivery Remove Licensing Remove Regulation
article thumbnail

BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC

The Pharma Data

With this acquisition we are expanding our product pipeline to include psychedelic therapeutics, incorporating elements of our IP around drug delivery technology in which we already have prototypes developed, which we believe will propel us towards clinical studies relatively quickly. Ahmad Doroudian, CEO of BetterLife.

article thumbnail

BetterLife Pharma Strengthens Board of Directors

The Pharma Data

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. About BetterLife Pharma Inc. BetterLife Pharma Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BetterLife Confirms Non-controlled Status of 2-bromo-LSD with Health Canada

The Pharma Data

According to Health Canada, “the information currently available at the Controlled Substances Directorate, 2-bromo-LSD is NOT CONTROLLED under the Schedules to the Controlled Drugs and Substances Act.”. The full Forbes article can be accessed here. BetterLife Pharma Inc.

article thumbnail

BetterLife’s Recent Acquisition: Taking LSD from Experimental to a Major Therapeutic Application

The Pharma Data

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. About BetterLife Pharma Inc. BetterLife Pharma Inc. For further information please visit www.abetterlifephama.com. About Transcend Biodynamics.

article thumbnail

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

The Pharma Data

Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.